AstraZeneca says advanced trial of breast-cancer drug Capivasertib meets primary endpoints

AstraZeneca PLC said Wednesday that Capivasertib plus Faslodex significantly improved progression-free survival when compared with Faslodex combined with a placebo in a Phase 3 trial in advanced hormone receptor-positive breast cancer.

The Anglo-Swedish pharma giant
AZN,
+1.30%

AZN,
+2.00%

said the trial met both primary endpoints of improving progression-free survival in the overall patient population and in a prespecified biomarker subgroup of patients whose tumors had qualifying alterations.

The trial will continue to assess overall survival as a key secondary endpoint, it said.

Breast cancer is the most common cancer in the world with an estimated 2.3 million patients diagnosed in 2020.

Write to Kyle Morris at [email protected]

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *